AN2 Therapeutics Q4 EPS $(0.57) Beats $(0.76) Estimate
AN2 Therapeutics +2.80% Pre
AN2 Therapeutics ANTX | 1.10 1.10 | +2.80% 0.00% Pre |
AN2 Therapeutics (NASDAQ:
ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.76) by 25 percent. This is a 6.56 percent increase over losses of $(0.61) per share from the same period last year.